Cycloadenosine meglumine injection

Cyclic adenosine monophosphate meglumine is a non-digitalis cardiotonic agent with a positive inotropic effect. It can enhance myocardial contractility, improve cardiac pumping function, dilate blood vessels, and reduce myocardial oxygen consumption. It can improve myocardial cell metabolism and protect ischemic and hypoxic myocardium. It can improve the function of sinoatrial node P cells.

The main ingredient of this product is cyclic adenosine monophosphate meglumine, which is the salt of cyclic adenosine monophosphate and meglumine (molar ratio 1:1).

It is used for heart failure, myocarditis, sick sinus syndrome, coronary heart disease and cardiomyopathy, and can also be used as an auxiliary treatment for arrhythmias.

1. Intravenous drip: dilute with 200-500 ml 5% glucose injection and then drip intravenously, once a day, 60-180 mg each time; 2. Intravenous push: dilute with 20-40 ml 25% or 10% glucose injection and then slowly push intravenously, once a day, 90 mg each time.

Occasionally, symptoms such as palpitations, heart palpitations, and dizziness may occur.

1. Those who are allergic to any ingredient in the drug. 2. This product is contraindicated for simultaneous intravenous administration with aminophylline.

This product is contraindicated for simultaneous intravenous administration with aminophylline.

Store in a cool and dark place

5ml:60mg

30 months.

Changchun Puhua Pharmaceutical Co., Ltd.

• Founded in:

  1997-11-28

• Address:

  No. 1105, Huoju Road, Changchun Hi-Tech Development Zone

• Tax NO.:

  91220101605912790E

• Registered Funds:

  53.4324 million yuan

• Website:

  Log in to view

• Email:

  Log in to view